Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by stock analysts at Piper Jaffray Cos. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday.
Several other brokerages also recently issued reports on SRPT. SunTrust Banks Inc. reiterated a “reduce” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 14th. Jefferies Group restated an “underperform” rating and set a $7.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. JMP Securities restated an “underperform” rating and set a $10.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. William Blair upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday. Finally, Janney Montgomery Scott upgraded shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $30.00 to $65.00 in a research report on Monday. Five research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. Sarepta Therapeutics currently has an average rating of “Hold” and an average price target of $27.66.
Sarepta Therapeutics (NASDAQ:SRPT) traded up 84.40% during mid-day trading on Monday, hitting $51.91. 23,109,510 shares of the company traded hands. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $52.30. The company’s market capitalization is $2.49 billion. The company’s 50-day moving average price is $26.16 and its 200 day moving average price is $20.47.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/sarepta-therapeutics-inc-srpt-upgraded-at-piper-jaffray-cos.html
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period last year, the business posted ($0.87) EPS. On average, analysts anticipate that Sarepta Therapeutics will post ($5.16) earnings per share for the current fiscal year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 10.90% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas increased its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. bought a new stake in Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at approximately $211,000. National Planning Corp increased its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the last quarter. Finally, First Allied Advisory Services Inc. increased its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the last quarter. 72.09% of the stock is owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.